中关村(000931.SZ)：盐酸丁螺环酮片一致性评价申报获受理

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets [1] Group 1: Company Developments - Beijing Huasu has received the acceptance notice for the consistency evaluation of Buprenorphine Hydrochloride Tablets in 5mg and 10mg specifications [1] - Buprenorphine is the first non-benzodiazepine anxiolytic drug, acting as a 5-HT1A receptor agonist to reduce excessive 5-HT activity in anxiety disorders [1] Group 2: Product Characteristics - The clinical advantage of Buprenorphine is its lack of drug dependence and withdrawal reactions, indicating a higher safety profile [1] - The indications for Buprenorphine Hydrochloride Tablets include various anxiety disorders [1]